XBP1 and familial pancreatic carcinoma: Both inhibitory molecules have proven to be effective against several pancreatic cancer and chronic lymphocytic leukemia (CLL) cell lines, wherein they inhibited the XBP1 splicing reaction in a dose-dependent manner.